Ilumetri 200 mg solution for injection in pre-filled syringe
Sponsors
Philipps-Universitaet Marburg, TOXILYON
Conditions
Ocular Sequelae in Lyell syndromechronic spontaneous urticaria
Phase 2
Tildrakizumab, an Anti-IL-23 Antibody for the Treatment of Refractory Chronic Spontaneous Urticaria – a single-arm, open-label, phase II study (TAILOR-CSU)
Not yet recruitingCTIS2024-513155-32-00
Target: 13Updated: 2025-09-15
Evaluation of Tildrakizumab in the Treatment of Ocular Sequelae in Lyell syndrome
Not yet recruitingCTIS2025-522556-10-01
Target: 10Updated: 2026-01-23